Kamada Ltd. KMDA NASDAQ · Healthcare · Israel
$8.09 -0.49% -$0.04
Summary
67 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: $75.3M against $11.7M.
- The share price is below the Bulios Fair Price.
- Out of every 100 USD of revenue, 13 USD is left as net profit.
- Revenue grew by 12% a year over the last 3 years.
What to watch
- Earnings per share swing sharply from year to year.
- 98% of profit goes to the dividend, leaving little room to raise it.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBy our assumptions the business is worth more than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 18.9 USD for 1 USD of yearly profit. Over the last five years it was 28.1 USD on average.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 6.3% a year over 5 years. Over the last 3 years it grew by 12% a year.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 58 USD
- Research and development 4.9 USD
- Sales and administration 21 USD
- Taxes and other 2.8 USD
- Net profit 13 USD
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 9.9 USD
Out of every 100 USD of revenue, 13 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
High, at risk- Yield
- 5.17%
- Paid out of profit
- 98%
You receive $0.42 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 5
- Hold 1
- Sell 0
Today's price within the analysts' price targets
The average target of $15 is 85% above today's price. 83% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Distribution Member 100%
By region
- Other Foreign Countries Member 41%
- Latin America 34%
- CANADA 15%
- Asia 9.4%
- Other Countries Member 0.1%
Distribution Member brings in 100% of revenue.
Segments in detail